Eva Couselo-Munoz - Publications

Correction: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: July 15, 2026

First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors.

Journal: Journal for immunotherapy of cancer

Published: May 19, 2026

Quality and safety of research biopsies in oncology clinical trials.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 21, 2026

Circulating immune and biochemical markers predict tumor response to immunotherapy in advanced melanoma and lung cancer.

Journal: Frontiers in immunology

Published: April 13, 2026

Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases.

Journal: Journal for immunotherapy of cancer

Published: March 31, 2026

Subcutaneous immunotherapy as a catalyst for decentralized, oncologist-led cancer care: a mixed-methods analysis.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: March 03, 2026

Biodistribution, shedding, and transmissibility of vusolimogene oderparepvec (RP1).

Journal: Frontiers in oncology

Published: January 28, 2026

Real-world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study.

Journal: Cancer

Published: November 11, 2025

Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial.

Journal: Nature medicine

Published: September 12, 2025

RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 08, 2025

Title: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: July 06, 2025

Poor efficacy of anti PD-1 antibody based immunotherapy in patients with acral melanoma: results from the Spanish Melanoma Group (GEM) registry.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: June 17, 2025